Safety and Efficacy of Talampanel in Glioblastoma Multiforme
Study Title
- Safety and Efficacy of Talampanel in Glioblastoma Multiforme
Teva Identifier
- IXR-207-21-189 / NABTT 0304
ClinicalTrials.gov Identifier
- NCT00267592
Study Status
- Completed
Trial Condition(s)
- Glioblastoma Multiforme
Interventions
- Drug: Talampanel | Radiation: Radiation Therapy (RT) 5 days a week + | Drug: temozolomide(TMZ) 75mg | Drug: adjuvant TMZ 200mg
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years and older
Trial Duration
- 12/01/2005 - 02/01/2011
Phase
- Phase 2
Study Type
Interventional
